- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
February 22, 2021Robins Kaplan Expands Health Care Litigation Group
-
February 1, 2021Meegan Hollywood Selected to Join American Antitrust Institute Advisory Board
-
January 28, 2021Human Rights Campaign Names Robins Kaplan LLP a “Best Place to Work for LGBTQ Equality” for the Thirteenth Consecutive Year
-
February 26, 2021Key Decisions Affecting Drug and Device Litigation in the Last Year
-
March 6, 2021With Our Voices 2021 Arc Gala
-
March 6, 20211st Annual Tee It Up for the Troops Winter Outing
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
February 3, 2021Navigating Software License Disputes in the Continuing Work-From-Home World
-
February 24, 2021Financial Daily Dose 2.24.2021 | Top Story: Chair Powell Promises Continued Fed Support for US Economy
-
February 23, 2021Financial Daily Dose 2.23.2021 | Top Story: SoftBank Nears Deal With WeWork’s Neumann for $500M Share Purchase
-
February 22, 2021Financial Daily Dose 2.22.2021 | Top Story: Boeing Grounds Some 777 Models After Engine Explosion on United Flight
Zofran
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
For further inquiries about Zofran, feel free to call us toll free at 1.800.553.9910, or send an e-mail by using the form.
Consumer Alert: Popular Anti-Nausea Drug Zofran Linked to Birth Defects
Zofran is an anti-nausea drug not FDA-approved for use during pregnancy, but often prescribed "off label" for morning sickness. It is associated with an increased risk of cleft palate and congenital heart defects.1
1 M. Anderka et al. Medications Used to Treat Nausea and Vomiting of Pregnancy and Risk of Selected Birth Defects. Birth Defects Res A Clin Mol Teratol. (Jan. 2012); JT Anderson et al. Ondansetron use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study. Pharmacoepidemiology and Drug Safety. (Oct. 2013)
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.